Black cisgender women in the Southern United States experience disproportionate human immunodeficiency virus (HIV) rates. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention tool but is underutilized in this population. We assessed PrEP cascade outcomes and correlates among Black women in the Southern United States. Between March and June 2022, we administered a cross-sectional online survey to Black cisgender women residing in the Southern United States who reported unprotected sex in the past 6 months and were negative for HIV by self-report. Participants provided information on sociodemographic characteristics, HIV knowledge, PrEP awareness and use, psychosocial factors, and health care access. We used descriptive statistics and multivariate logistic regression models to describe the sample and assess the correlates of PrEP outcomes, respectively. Participants included 491 Black women, with a mean age of 40.1 years (SD: 17.5); 53% had a college degree or lower, and 79% were single. PrEP awareness was 39.5%, willingness 25.7%, and current use only 5.5%. The factors associated with PrEP awareness included younger age (aOR = 1.02, 95% CI: 1.01–1.03), higher education (aOR = 1.68, 95% CI: 1.09–2.60), medical trust (aOR = 1.09, 95% CI: 1.03–1.15), binge drinking (aOR = 1.77, 95% CI: 1.06–2.94), and HIV testing in the past year (aOR = 1.55, 95% CI: 0.98–2.45). The PrEP willingness predictors included HIV testing in the past year (aOR = 1.80, 95% CI: 1.11–2.90) and HIV worry (aOR = 1.84, 95% CI: 1.09–3.09). HIV testing emerged as a key facilitator for both PrEP awareness and willingness, suggesting that testing encounters represent critical opportunities for PrEP integration. PrEP strategies should address both individual-level factors and structural barriers, particularly medical trust within health care systems.
SullivanPS, Satcher JohnsonA, PembletonES, et al.Epidemiology of HIV in the USA: Epidemic burden, inequities, contexts, and responses. Lancet, 2021; 397(10279):1095–1106; doi: 10.1016/s0140-6736(21)00395-0
5.
Center for Disease Control and Prevention. HIV surveillance supplemental report: Estimated HIV incidence and prevalence in the United States, 2018–2022. 2024. Available from: https://stacks.cdc.gov/view/cdc/156513 [Last accessed: 27August 2025].
U.S. Public Health Services. Pre-exposure prophylaxis for the prevention of HIV infection in the United States-2021 Update. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 [Last accessed: 14April 2025].
BaetenJM, DonnellD, NdaseP, et al.; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med, 2012; 367(5):399–410; doi: 10.1056/NEJMoa1108524
11.
McCormackS, DunnDT, DesaiM, et al.Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet, 2016; 387(10013):53–60; doi: 10.1016/s0140-6736(15)00056-2
12.
ThigpenMC, KebaabetswePM, PaxtonLA, et al.; TDF2 Study Group. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med, 2012; 367(5):423–434; doi: 10.1056/NEJMoa1110711
13.
NunnAS, Brinkley-RubinsteinL, OldenburgCE, et al.Defining the HIV pre-exposure prophylaxis care continuum. AIDS, 2017; 31(5):731–734; doi: 10.1097/qad.0000000000001385
14.
KelleyCF, KahleE, SieglerA, et al.Applying a PrEP continuum of care for men who have sex with men in Atlanta, Georgia. Clin Infect Dis, 2015; 61(10):1590–1597; doi: 10.1093/cid/civ664
15.
OjikutuBO, Amutah-OnukaghaN, MahoneyTF, et al.HIV-related mistrust (or HIV conspiracy theories) and willingness to use PrEP among Black Women in the United States. AIDS Behav, 2020; 24(10):2927–2934; doi: 10.1007/s10461-020-02843-z
16.
OjikutuBO, BogartLM, Higgins-BiddleM, et al.Facilitators and barriers to pre-exposure prophylaxis (PrEP) use among Black individuals in the United States: Results from the National Survey on HIV in the Black community (NSHBC). AIDS Behav, 2018; 22(11):3576–3587; doi: 10.1007/s10461-018-2067-8
17.
TrossS, SpectorAY, ErtlMM, et al.A qualitative study of barriers and facilitators of PrEP uptake among women in substance use treatment and syringe service programs. AIDS Behav, 2023; 27(4):1162–1172; doi: 10.1007/s10461-022-03853-9
18.
NydeggerLA, Dickson-GomezJ, KoTK. Structural and syndemic barriers to PrEP adoption among Black women at high risk for HIV: A qualitative exploration. Cult Health Sex, 2021; 23(5):659–673; doi: 10.1080/13691058.2020.1720297
19.
NydeggerLA, KidaneH, BenitezS, et al.A qualitative exploration of PrEP interests, barriers, and interventions among Black and Latina cisgender women in the U.S. Arch Sex Behav, 2024; 53(2):771–783; doi: 10.1007/s10508-023-02712-5
20.
SmitF, MasvawureTB. Barriers and facilitators to acceptability and uptake of pre-exposure prophylaxis (PrEP) among Black women in the United States: A systematic review. J Racial Ethn Health Disparities, 2024; 11(5):2649–2662; doi: 10.1007/s40615-023-01729-9
21.
PriceDM, GarretsonM, CaiX, et al.Knowledge and attitudes about HIV pre-exposure prophylaxis among sexually active Black and Latina cisgender women: Findings from the 2017 and 2018 New York City sexual health survey. AIDS Patient Care STDS, 2024; 38(9):428–437; doi: 10.1089/apc.2024.0142
22.
ScottRK, HullSJ, HuangJC, et al.Intention to initiate HIV Pre-exposure prophylaxis among cisgender women in a high HIV prevalence U.S. City. Womens Health Issues, 2023; 33(5):541–550; doi: 10.1016/j.whi.2023.05.009
23.
HullSJ, DuanX, BrantAR, et al.Understanding psychosocial determinants of PrEP uptake among cisgender women experiencing heightened HIV risk: Implications for multi-level communication intervention. Health Commun, 2023; 38(14):3264–3275; doi: 10.1080/10410236.2022.2145781
24.
AaronE, BlumC, SeidmanD, et al.Optimizing delivery of HIV pre-exposure prophylaxis for women in the United States. AIDS Patient Care STDS, 2018; 32(1):16–23; doi: 10.1089/apc.2017.0201
25.
ConleyC, JohnsonR, BondK, et al.US Black cisgender women and pre-exposure prophylaxis for human immunodeficiency virus prevention: A scoping review. Womens Health (Lond), 2022; 18:17455057221103098; doi: 10.1177/17455057221103098
26.
BradleyELP, HooverKW, Centers for Disease Control and Prevention Women and PrEP Discussion Series Team. Improving HIV pre-exposure prophylaxis implementation for women: Summary of key findings from a discussion series with women’s HIV prevention experts. Womens Health Issues, 2019; 29(1):3–7; doi: 10.1016/j.whi.2018.08.004
27.
PyraM, JohnsonAK, DevlinS, et al.HIV pre-exposure prophylaxis use and persistence among Black ciswomen: “Women need to protect themselves, period. J Racial Ethn Health Disparities, 2022; 9(3):820–829; doi: 10.1007/s40615-021-01020-9
28.
AladeT, HullS, SinksH, et al.Medical distrust and the intention to initiate pre-exposure prophylaxis in Black cisgender women. AIDS Patient Care STDS, 2025; 39(7):273–280; doi: 10.1089/apc.2025.0043
29.
SullivanPS, MenaL, ElopreL, et al.Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep, 2019; 16(4):259–269; doi: 10.1007/s11904-019-00447-4
Sims HaynesA, MarkhamC, SchickV, et al.A systematic review and narrative synthesis of factors affecting pre-exposure prophylaxis willingness among Black women for HIV prevention. AIDS Behav, 2025; 29(1):101–132; doi: 10.1007/s10461-024-04491-z
32.
TroutmanJ, IngramLA, GaddistB, et al.African American women’s current knowledge, perceptions, and willingness of PrEP use for HIV prevention in the South. J Healthc Sci Humanit, 2021; 11(1):51–72.
33.
Center for Disease Control and Prevention. Clinical guidance for PrEP. HIV Nexus. Updated March 5. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html [Last accessed: May20, 2025].
34.
BlashillAJ, BradyJP, RooneyBM, et al.Syndemics and the PrEP cascade: Results from a sample of young Latino men who have sex with men. Arch Sex Behav, 2020; 49(1):125–135; doi: 10.1007/s10508-019-01470-7
35.
ThompsonHS, ValdimarsdottirHB, WinkelG, et al.The group-based medical mistrust scale: Psychometric properties and association with breast cancer screening. Prev Med, 2004; 38(2):209–218; doi: 10.1016/j.ypmed.2003.09.041
36.
KleinH, WashingtonTA. The pre-exposure prophylaxis (PrEP) stigma scale: Preliminary findings from a pilot study. Int Public Health J, 2019; 11(2):185–195.
OldfieldBJ, EdelmanEJ. Addressing unhealthy alcohol use and the HIV pre-exposure prophylaxis care continuum in primary care: A scoping review. AIDS Behav, 2021; 25(6):1777–1789; doi: 10.1007/s10461-020-03107-6
39.
OglesbyWH, AlemagnoSA. Psychometric properties of an HIV knowledge scale administered with populations at high risk for HIV infection. Health Promot Pract, 2013; 14(6):859–867; doi: 10.1177/1524839912470453
40.
ClementME, JohnstonBE, EagleC, et al.Advancing the HIV pre-exposure prophylaxis continuum: A collaboration between a Public Health Department and a federally qualified Health Center in the Southern United States. AIDS Patient Care STDS, 2019; 33(8):366–371; doi: 10.1089/apc.2019.0054
41.
CollierKL, ColarossiLG, SandersK. Raising awareness of pre-exposure prophylaxis (PrEP) among women in New York City: Community and provider perspectives. J Health Commun, 2017; 22(3):183–189; doi: 10.1080/10810730.2016.1261969
42.
KiptinnessC, KuoAP, ReedyAM, et al.Examining the use of HIV self-testing to support PrEP delivery: A systematic literature review. Curr HIV/AIDS Rep, 2022; 19(5):394–408; doi: 10.1007/s11904-022-00617-x
43.
TaggartT, LiangY, PinaP, et al.Awareness of and willingness to use PrEP among Black and Latinx adolescents residing in higher prevalence areas in the United States. PLoS One, 2020; 15(7):e0234821; doi: 10.1371/journal.pone.0234821
44.
ScottRK, HullSJ, RichardsRC, et al.Awareness, acceptability, and intention to initiate HIV pre-exposure prophylaxis among pregnant women. AIDS Care, 2022; 34(2):201–213; doi: 10.1080/09540121.2021.1916870
45.
TekesteM, HullS, DovidioJF, et al.Differences in medical mistrust between Black and White women: Implications for patient-provider communication about PrEP. AIDS Behav, 2019; 23(7):1737–1748; doi: 10.1007/s10461-018-2283-2
46.
HirschhornLR, BrownRN, FriedmanEE, et al.Black cisgender women’s PrEP knowledge, attitudes, preferences, and experience in Chicago. J Acquir Immune Defic Syndr, 2020; 84(5):497–507; doi: 10.1097/qai.0000000000002377
47.
JohnsonAK, PyraM, DevlinS, et al.Provider perspectives on factors affecting the PrEP care continuum among Black cisgender women in the Midwest United States: Applying the consolidated framework for implementation research. J Acquir Immune Defic Syndr, 2022; 90(S1):S141–S148; doi: 10.1097/qai.0000000000002974
HiersK. Implementing the Trump Administration’s “Ending the HIV epidemic” Plan in the Southern United States. Am J Public Health, 2020; 110(1):32–33; doi: 10.2105/ajph.2019.305452
50.
ArredondoK, TouchettHN, KhanS, et al.Current programs and incentives to overcome rural physician shortages in the United States: A narrative review. J Gen Intern Med, 2023; 38(Suppl 3):916–922; doi: 10.1007/s11606-023-08122-6
51.
CalabreseSK, DovidioJF, TekesteM, et al.HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr, 2018; 79(1):46–53; doi: 10.1097/qai.0000000000001762
52.
GolubSA. PrEP stigma: Implicit and explicit drivers of disparity. Curr HIV/AIDS Rep, 2018; 15(2):190–197; doi: 10.1007/s11904-018-0385-0
53.
DaleSK, PetrullaV, WrightIA. A pilot randomized control trial of the motivational interviewing to increase PrEP uptake intervention among Black women in the United States. AIDS Patient Care STDS, 2024; 38(11):517–529; doi: 10.1089/apc.2024.0189
54.
ClementME, PerryB, McKennaK, et al.Identifying implementation strategies to enhance HIV pre-exposure prophylaxis uptake among Black cisgender women in New Orleans, Louisiana. AIDS Patient Care STDS, 2024; 38(3):144–150; doi: 10.1089/apc.2023.0300
